PAVmed Inc. (PAVM)
NASDAQ: PAVM
· Real-Time Price · USD
0.82
0.10 (13.17%)
At close: May 01, 2025, 3:59 PM
0.82
-0.61%
After-hours: May 01, 2025, 04:12 PM EDT
13.17% (1D)
| Bid | 0.74 |
| Market Cap | 14.16M |
| Revenue (ttm) | 3M |
| Net Income (ttm) | 39.79M |
| EPS (ttm) | 0.5 |
| PE Ratio (ttm) | 1.65 |
| Forward PE | -1.79 |
| Analyst | Strong Buy |
| Ask | 0.92 |
| Volume | 130,553 |
| Avg. Volume (20D) | 166,126 |
| Open | 0.77 |
| Previous Close | 0.72 |
| Day's Range | 0.76 - 0.84 |
| 52-Week Range | 0.55 - 2.43 |
| Beta | 1.14 |
About PAVM
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation...
Industry Medical - Devices
Sector Healthcare
IPO Date Jul 27, 2016
Employees 39
Stock Exchange NASDAQ
Ticker Symbol PAVM
Website https://www.pavmed.com
Analyst Forecast
According to 1 analyst ratings, the average rating for PAVM stock is "Strong Buy." The 12-month stock price forecast is $19.5, which is an increase of 2263.64% from the latest price.
Stock ForecastsNext Earnings Release
PAVmed Inc. is scheduled to release its earnings on May 15, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+7.31%
PAVmed shares are trading higher on possible conti...
Unlock content with
Pro Subscription
